FogPharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
FogPharma - overview
Established
2016
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2016, Fog Pharmaceuticals, Inc. operates as a biotechnology company that focuses on developing cell-penetrating miniprotein medicines for the treatment of cancer. The company was founded by its CEO, Greg Verdine. In March 2024, FogPharma raised USD 145 million in Series E funding led by Nextech, with participation from ARCH Venture Partners, Fidelity Investments, GV, Cormorant Asset Management, T.
Rowe Price, Farallon Capital Management, VenBio Partners, and Milky Way Ventures. The company provides CPMPs (Cell-penetrating mini proteins) that target cancer-causing proteins inside cancer cells. The CPMPs platform includes Helicons, Pro-locks, and Griptides. Fog Pharmaceuticals plans to use the proceeds from its March 2024 funding to advance its first-and-only-in-class direct ß-catenin antagonist into clinical development to potentially address 20% or more of all cancers.
Current Investors
GV, Boyu Capital, Leerink Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.fogpharma.com
Company Stage
Series E
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.